Verubecestat: Another one bites the dust?

by Joshua Grill, PhD February 15, 2017

Merck announced on Tuesday, February 14, that yet another clinical trial of a promising Alzheimer’s disease drug had failed. The trial was testing the safety and efficacy of verubecestat, an oral therapy that, at some doses, can reduce amyloid beta production by as much as 90% (Kennedy et al., Science 2016). more >

“What can we learn from the sleeping brain?”

The 23rd UCI Distinguished Lecture Series on Brain, Learning, and Memory hosted by UCI MIND, UCI Ayala School of Biological Sciences, and UCI Center for the Neurobiology of Learning and Memory was held on February 7, 2017, at the Irvine Barclay Theatre.

more >

“Patients ‘relieved’ by amyloid scans” 


MedPage Today

February 8, 2017

Learn more about a recent research study conducted by UCI MIND Co-Director, Dr. Joshua Grill, and colleagues to better understand patient and caregiver reactions to clinical amyloid imaging.

Read more> more >

Research Suggests Space Travel Affects the Brain

U.S. News & World Report
February 6, 2017

“This is not a deal-breaker,” co-author Charles Limoli, a neurobiologist at the University of California, Irvine, said last fall. “I do not think that during the course of a trip to Mars and back the astronauts will come back with anything remotely similar to full-blown Alzheimer’s. more >

Join us! Feb 7 Distinguished Lecture with Dr. Ruth Benca

Please join UCI MIND, UCI CNLM, and the Ayala School of Biological Sciences on February 7, 2017 @ 7:30 PM for the 23rd UC Irvine Distinguished Lecture Series on Brain, Learning and Memory. Dr. Ruth Benca, renowned sleep medicine expert and Professor and Chair for the Department of Psychiatry and Human Behavior, will present a lecture on “What can we learn from the sleeping brain?” 

Sleep is a universal and fundamental process that is present in every animal species and occupies a third of our lives. more >

Solanezumab fails in Phase 3: What do we know?

December 6, 2016

Joshua Grill, PhD, and Aimee Pierce, MD

screen-shot-2016-12-05-at-9-35-47-amThis week, at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting in San Diego, we will likely learn more about the recent announcement from Eli Lilly and company that their Phase 3 clinical trial of the monoclonal antibody against the soluble form of beta amyloid, solanezumab, did not demonstrate adequate efficacy to pursue approval from the U.S. more >

UCI MIND featured on KCAL9/CBS2 2 nights in a row

December 1, 2016


If you missed UCI MIND Gala Co-Chairs, Lucy &  Roger Lisabeth, on KCAL 9 last night, tune into CBS 2 Los Angeles tonight at 5pm with Elsa Ramon to hear their powerful story.

Learn more about what the Lisabeths and UCI MIND are doing in the fight against Alzheimer’s disease here. more >

UCI MIND on 60 Minutes


alzmainNovember 28, 2016

60 Minutes

Did you hear UCI MIND researcher Dr. Claudia Kawas last night on 60 Minutes? Click here to read the script and learn more.




  more >

A December to Remember Gala Honoree Dr. Ira Lott

ira-t-lott-picture-2010Ira T. Lott, M.D. is the Director of the UCI MIND Down Syndrome Program and Professor Emeritus of UC Irvine School of Medicine. While focused on helping people with Down syndrome, Dr. Lott is also expanding knowledge about Alzheimer’s disease in the general population. more >

A December to Remember Gala Honorees Burton & Linda Young

img_6059Join us in honoring our 2016 Community Leadership Honorees, Linda Young and Burton Young, at A December to Remember Gala on December 3 at the Balboa Bay Resort in Newport Beach.

Linda and Burton have worked tirelessly to increase research funding for treatments and a cure for Alzheimer’s disease at UCI MIND. more >